VEGFA and hepatocellular carcinoma: Sorafenib is an oral multikinase inhibitor with activity against vascular endothelial growth factor (VEGF) signaling.3 Elucidation of the importance of angiogenesis in driving HCC biology provided further rationale for testing of anti‐VEGF therapies.4 Siegel et al conducted a phase II trial of bevacizumab, a recombinant humanized monoclonal antibody against VEGF, for the treatment of nonmetastatic HCC.